Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 251

1.

Adeno-associated virus vector-mediated systemic delivery of IFN-beta combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models.

Streck CJ, Dickson PV, Ng CY, Zhou J, Gray JT, Nathwani AC, Davidoff AM.

Clin Cancer Res. 2005 Aug 15;11(16):6020-9.

2.

The efficacy of combination therapy using adeno-associated virus--interferon beta and trichostatin A in vitro and in a murine model of neuroblastoma.

Hamner JB, Sims TL, Cutshaw A, Dickson PV, Rosati S, McGee M, Ng CY, Davidoff AM.

J Pediatr Surg. 2008 Jan;43(1):177-82; discussion 182-3. doi: 10.1016/j.jpedsurg.2007.09.048.

PMID:
18206478
3.

Adeno-associated virus vector-mediated delivery of pigment epithelium-derived factor restricts neuroblastoma angiogenesis and growth.

Streck CJ, Zhang Y, Zhou J, Ng C, Nathwani AC, Davidoff AM.

J Pediatr Surg. 2005 Jan;40(1):236-43.

PMID:
15868591
4.
5.

Intravascular administration of tumor tropic neural progenitor cells permits targeted delivery of interferon-beta and restricts tumor growth in a murine model of disseminated neuroblastoma.

Dickson PV, Hamner JB, Burger RA, Garcia E, Ouma AA, Kim SU, Ng CY, Gray JT, Aboody KS, Danks MK, Davidoff AM.

J Pediatr Surg. 2007 Jan;42(1):48-53.

PMID:
17208540
6.

Interferon beta-mediated vessel stabilization improves delivery and efficacy of systemically administered topotecan in a murine neuroblastoma model.

Dickson PV, Hagedorn NL, Hamner JB, Fraga CH, Ng CY, Stewart CF, Davidoff AM.

J Pediatr Surg. 2007 Jan;42(1):160-5; discussion 165.

PMID:
17208558
7.
8.

Suppression of cancer growth in mice by adeno-associated virus vector-mediated IFN-beta expression driven by hTERT promoter.

He LF, Wang YG, Xiao T, Zhang KJ, Li GC, Gu JF, Chu L, Tang WH, Tan WS, Liu XY.

Cancer Lett. 2009 Dec 28;286(2):196-205. doi: 10.1016/j.canlet.2009.05.024. Epub 2009 Jun 28.

PMID:
19564073
9.

rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice.

Davidoff AM, Nathwani AC, Spurbeck WW, Ng CY, Zhou J, Vanin EF.

Cancer Res. 2002 Jun 1;62(11):3077-83.

10.
11.

Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin.

Zhang X, Xu J, Lawler J, Terwilliger E, Parangi S.

Clin Cancer Res. 2007 Jul 1;13(13):3968-76.

12.

Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.

Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS.

Cancer Res. 2002 May 15;62(10):2731-5.

14.
15.

Enhanced antitumor effect of combining interferon beta with TRAIL mediated by tumor-targeting adeno-associated virus vector on A549 lung cancer xenograft.

Wang Y, He L, He G, Kong Y, Liu X, Cai H, Liu X, Tan W.

Sheng Wu Gong Cheng Xue Bao. 2010 Jun;26(6):780-8.

PMID:
20815258
16.

Restriction of neuroblastoma angiogenesis and growth by interferon-alpha/beta.

Streck CJ, Zhang Y, Miyamoto R, Zhou J, Ng CY, Nathwani AC, Davidoff AM.

Surgery. 2004 Aug;136(2):183-9.

PMID:
15300178
17.

Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity.

Odaka M, Sterman DH, Wiewrodt R, Zhang Y, Kiefer M, Amin KM, Gao GP, Wilson JM, Barsoum J, Kaiser LR, Albelda SM.

Cancer Res. 2001 Aug 15;61(16):6201-12.

18.

Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma.

Wang Y, Huang F, Cai H, Zhong S, Liu X, Tan WS.

J Gene Med. 2008 May;10(5):518-26. doi: 10.1002/jgm.1177.

PMID:
18338833
19.

AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer.

Nie B, Shen Z, Wen JB, Wong OG, Hsueh WD, Huo LF, Kung HF, Jiang B, Lin MC.

Mol Cancer Ther. 2008 Sep;7(9):2855-65. doi: 10.1158/1535-7163.MCT-08-0366.

20.

mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.

Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, Wacheck V.

Anticancer Res. 2008 Nov-Dec;28(6A):3801-8.

Supplemental Content

Support Center